Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.81 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.81 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | CDC42 | P60953 | 1/20 | 0.81 |
| ▸ | RAC1 | P63000 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116646 | 1.00 | PTGS2 (0.81) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| SCHEMBL12090593 | 1.00 | PTGS2 (0.81) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| SCHEMBL20887114 | 1.00 | PTGS2 (0.81) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL2345440 | 0.90 | AKR1C3 (0.94) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 0.90 | AKR1C3 (1.00) | PTGS2AKR1C3AKR1C2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021068884-A1 | POLYPEPTIDE DERIVATIVE, NANOFIBER AND APPLICATION THEREOF | 南开大学 | 2021-04-15 | — | — | WO | disclosed |
| WO-2021032088-A1 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND | 上海众强药业有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-12 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| WO-2019071153-A1 | PROGRAMMABLE DENDRITIC DRUGS | SONY CORPORATION (JP) | 2019-04-11 | — | — | WO | disclosed |
| US-10007042-B2 | Composition, light reflecting film, luminance-improving film, backlight unit, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| EP-2694079-B1 | POLYMERS AND METHODS FOR THE TREATMENT OF PAIN | UNIV RUTGERS (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170010398-A1 | COMPOSITION, LIGHT REFLECTING FILM, LUMINANCE-IMPROVING FILM, BACKLIGHT UNIT, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2017-01-12 | — | — | US | disclosed |
| US-7932264-B2 | Sinomenine derivatives and preparation and uses thereof | NATUREMED GROUP CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2009124371-A9 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2010-12-02 | — | — | WO | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2009124371-A2 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2009-10-15 | — | — | WO | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20080318966-A1 | Sinomenine Derivatives and Preparation and Uses Thereof | NIMBUS INNOWORKS LIMITED (CN) | 2008-12-25 | — | — | US | disclosed |
| US-20080318966-A1 | Sinomenine Derivatives and Preparation and Uses Thereof | NIMBUS INNOWORKS LIMITED (CN) | 2008-12-25 | — | — | US | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
| US-4420639-A | Aromatic compounds | BEECHAM GROUP LIMITED (GB) | 1983-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | PARP1, PARP11, PHOSPHO1 | PTGS2 4298/4885AKR1C3 1892/4885AKR1C2 2704/4885 |
| US-20080318966-A1 | Sinomenine Derivatives and Preparation and Uses Thereof | OPRM1, SIN3A, MIF | PTGS2 82/4885AKR1C3 1361/4885AKR1C2 2243/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PTGS2 4265/4885AKR1C3 2546/4885AKR1C2 2397/4885 |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PTGS2 6/4885AKR1C3 568/4885AKR1C2 1264/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PTGS2 4265/4885AKR1C3 2546/4885AKR1C2 2397/4885 |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 440/4885AKR1C3 948/4885AKR1C2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.